Current multiple myeloma treatment strategies with novel agents: a European perspective
about
Shear flow-induced formation of tubular cell protrusions in multiple myeloma cells.Time-dependent endpoints as predictors of overall survival in multiple myelomaPomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)Case report on renal failure reversal in lambda chain multiple myeloma with bortezomib and dexamethasone.Platelet factor-4 and its p17-70 peptide inhibit myeloma proliferation and angiogenesis in vivoTargeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell linesThe small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells.Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone.European perspective on multiple myeloma treatment strategies: update following recent congressesDiagnostic and therapeutic approaches to multiple myeloma patients: 'Real-world' data from representative multicentre treatment surveys in Germany between 2008 and 2011.BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic miceConsensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.Multiple myeloma treatment strategies with novel agents in 2011: a European perspectiveManagement of myeloma-associated renal dysfunction in the era of novel therapies.Emerging biological insights and novel treatment strategies in multiple myeloma.Perspectives in the treatment of multiple myeloma.An old drug with a new future: bendamustine in multiple myeloma.Is high cut-off hemodialysis effective in myeloma kidney?Current treatment landscape for relapsed and/or refractory multiple myeloma.Modulation of cereblon levels by anti-myeloma agents.Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma.Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity.Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide.Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation.Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.Impaired efferocytosis by monocytes in multiple myeloma.Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma.Characteristics and outcomes of patients with multiple myeloma : Data from a developing country.
P2860
Q30501430-556E4522-539C-458A-94E8-8EDE8C809615Q30538040-BB5C0E44-8CA1-42C9-B4BF-82C17CC1CA7DQ30802505-7ADF7B9D-F26D-4BED-901E-BF4620652B3DQ31094748-6A03F75B-A1CA-4DD0-94E1-2201E716A7EEQ33874209-41485CB7-A6B2-4EFE-8B97-04D9C796E27BQ33938595-05CFA8AF-6649-4FC4-8993-2F49292FA3FBQ34081748-DEC17A23-061F-43DA-8005-008EDE753178Q34227679-566BDAEA-5CED-44F9-BF4B-23AC175DA86FQ34420112-D80F0819-61A5-44D0-86E2-D9AC7FEA71A4Q35989943-B6DC10D5-CEE7-419F-A479-E3CDC46328DEQ36254820-C5D8A9A2-7322-4125-A880-C1DD63FA3962Q37197900-AA9C879F-44FA-4215-B80E-41BBDA64B308Q37761370-DD740ABE-C05E-46AA-942D-3DA9FC33E684Q37858327-CFFB6A63-D471-4AD1-A1D3-0E7DF2671208Q37978343-92B99607-7726-4AF9-B61B-A1F586EB9EC8Q38037600-2432BADA-9F84-4F40-8C6B-D029AACCFCEFQ38108391-D48520C5-5055-42D4-8F0E-D3A3699B9263Q38139989-A334C432-65C7-4129-B5E9-51F2FA487892Q38199171-4CF77953-29D3-4334-89B6-6DE490E1263CQ38271032-C912EB84-9171-4487-BB19-002661CB8183Q38888980-943A9703-BFD5-47A6-8814-631E54CCD889Q39583526-9096B841-4753-459F-89C7-3A2DEA1E1131Q40621650-B9D4FED2-6417-4267-B632-8C2DAEF740C2Q40647620-74F4F5B7-2FBA-4AB0-96AA-41C6AF192F80Q42184785-D14FD383-6392-41A3-805C-D7082C64D3C3Q55058300-AE3819AF-766A-45E2-A7B0-687B82B61760Q55310900-45DAC6E0-9F69-470C-8E03-59C9A1AEBFF5Q55383806-ED3735EB-D96D-4B2E-B871-4C5097B98ABDQ55515927-441A44CC-A8B6-4E13-A03B-8CE680B9E73D
P2860
Current multiple myeloma treatment strategies with novel agents: a European perspective
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current multiple myeloma treatment strategies with novel agents: a European perspective
@en
Current multiple myeloma treatment strategies with novel agents: a European perspective.
@nl
type
label
Current multiple myeloma treatment strategies with novel agents: a European perspective
@en
Current multiple myeloma treatment strategies with novel agents: a European perspective.
@nl
prefLabel
Current multiple myeloma treatment strategies with novel agents: a European perspective
@en
Current multiple myeloma treatment strategies with novel agents: a European perspective.
@nl
P2093
P2860
P50
P921
P1433
P1476
Current multiple myeloma treatment strategies with novel agents: a European perspective
@en
P2093
Jamie Cavenagh
Jean-Luc Harousseau
Jesús San Miguel
Joan Bladé
Johannes Drach
Mario Boccadoro
Martin Kropff
Meral Beksac
Nicolas Ketterer
Ofer Shpilberg
P2860
P356
10.1634/THEONCOLOGIST.2009-0203
P50
P577
2010-01-19T00:00:00Z